Food Allergy Fund Innovators Research Grants

The Food Allergy Fund Innovators Research Grants aim to support innovative research addressing the root causes of food allergies. This initiative invites academic investigators and early-stage companies to submit proposals on a rolling basis. Grants ranging from $75,000 to $250,000 are available for one or two years, with a focus on collaboration and innovation. Proposals will be reviewed by a Scientific Advisory Board, emphasizing the importance of interdisciplinary approaches in tackling food allergy challenges.

Note: The deadline for submission of Letters of Intent is indicated above as the due date for Letters of Inquiry.
The Food Allergy Fund is the leading nonprofit dedicated to funding food allergy research. FAF's grants support the creation of new treatments that will address the root causes of food allergies. Through our ground-breaking research and unique thought leadership summits, we accelerate innovation to find solutions.
Food Allergy Fund Request for Proposals
We’re committed to bridging the funding gap for scientific research into food allergies and are accepting Letters of Intent for three of our leading programs: The Microbiome Collective, the Drug Repurposing Program and Innovators Research Grants.
On a rolling basis, FAF will award grants to the researcher or team of researchers who demonstrate the most innovative approach to identifying what causes food allergies or an improved treatment.
Proposals will be reviewed by FAF’s Scientific Advisory Board and scored on the NIH scoring scale (1-9). Innovation and collaboration (across disciplines and/or institutions) will be prioritized in the scoring process. The top scoring candidates based on the letter of intent and CV will be notified and requested to submit more detailed proposals.
Grant indirect costs are capped at 10%.
Suggested annual funding tiers are $75,000, $150,000, and $250,000. Requests outside these tiers will be considered on a case-by-case basis.
Grants may be awarded for terms of one or two years.

Eligibility

This RFP is open to academic investigators, university spinouts, and early-stage companies. Teams should have adequate pharmaceutical expertise or microbiome, genetic and human clinical trial expertise to document an eventual developmental approach for human use.